Here are the 10-K annual reports from Neurogene, Inc. (NGNE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow NGNE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NGNE filings page.
Neurogene Inc. is a clinical-stage biotech focused on genetic medicines for severe neurological diseases, led by NGN-401, a gene therapy for Rett syndrome using its proprietary EXACT transgene regulation platform and in-house AAV manufacturing.
The Phase 3 Embolden trial of NGN-401 is fully enrolled, with over half of participants dosed, and prior Phase 1/2 data showed functional gains and generally well-tolerated safety at the 1E15 vg dose. NGN-401 has received Breakthrough Therapy, RMAT and PRIME designations and was selected for the FDA’s START pilot program.
Neurogene remains pre-revenue and deeply loss-making, reporting a net loss of $90.4 million in 2025 versus $75.1 million in 2024, with an accumulated deficit of $352.6 million as of December 31, 2025. Cash, cash equivalents and short-term investments totaled $269.0 million, and management expects to need substantial additional capital as it advances clinical programs and scales its 42,000-square-foot Houston cGMP facility. As of March 18, 2026, the company had 15,574,293 common shares outstanding.